Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
Rib-X raises $18.7M for trial of skin infection drug
Rib-X Pharmaceuticals, which specializes in infectious disease drugs, secured $18.7 million in the first tranche of a stock financing round targeted at $67.5 million. The firm will use the proceeds to fund a late-stage trial of delafloxacin, an advanced antibiotic designed to treat acute bacterial skin and skin structure infections such as methicillin-resistant Staphylococcus aureus.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .